Treatment of heart failure with fosinopril: An angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion

American Journal of Hypertension

Volumn 10, Issue 10 II SUPPL., 1997, Pages

  Mancia, Giuseppe ^a,b   Giannattasio, Cristina ^a,b   Grassi, Guido ^a,b  

^a SAN GERARDO HOSPITAL   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Angiotensin converting enzyme inhibitors; Arterial compliance; Congestive heart failure; Fosinopril; Reflex control of circulation; Sympathetic activity

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL;

ARTERY COMPLIANCE; ARTICLE; CONGESTIVE HEART FAILURE; DRUG BLOOD LEVEL; DRUG EXCRETION; HEMODYNAMICS; HUMAN; PRIORITY JOURNAL;

EID: 0030830924     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(97)00329-4     Document Type: Article

References (28)

1. Ho KKL, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure the Framingham study . J Am Coll Cardiol. 22(suppl A):1993;6A-13A.
2. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure the Framingham study . N Engl J Med. 285:1971;1441-1442.
3. Effects of enalapril in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study . N Engl J Med. 316:1987;1429-1435.
4. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 325:1991;293-302.
5. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
6. Konstam MA, Kronenberg MW, Rousseau MF, et al. effects of the angiotensin-converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation. 88:1993;2277-2283.
7. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the Survival And Ventricular Enlargement trial . N Engl J Med. 327:1992;669-677.
8. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 311:1984;819-823.
9. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 92:1995;3206-3211.
10. Grassi G, Seravalle G, Calhoun DA, et al. Monitoring of sympathetic activity in man physiology and pharmacology . Eur Heart J. 13(suppl A):1992;22-25.
11. Davis D, Baily R, Zelis R. Abnormalities in systemic norepinephrine kinetics in human congestive heart failure. Am J Physiol. 254:1988;759-766.
12. Grassi G, Lanfranchi A, Seravalle G, et al. Effects of chronic angiotensin-converting enzyme inhibition on sympathetic nerve traffic in congestive heart failure (abst). Eur Heart J. 14(suppl):1994;341.
13. Lanfranchi A, Cattaneo BM, Bolla GB, et al. Effects of angiotensin-converting enzyme inhibition on baroreflex control of circulation in congestive heart failure (abst). Eur Heart J. 16(suppl):1995;454.
14. Mancia G, Mark AL: Arterial baroreflexes in humans, in Shepherd JT, Abboud FM (eds): Handbook of Physiology: The Cardiovascular System, vol. II, part 2. American Physiological Society, Bethesda, MD, 1983, pp 756-793.
15. Mancia G, Seravalle G, Giannattasio C, et al. Reflex cardiovascular control in congestive heart failure. Am J Cardiol. 69:1992;17G-23G.
16. Ferguson DW. Sympathetic mechanisms in heart failure Pathophysiological and pharmacological implications . Circulation. 87(suppl VII):1993;68-75.
17. Giannattasio C, Failla M, Stella ML, et al. Alterations of radial artery compliance in patients with congestive heart failure. Am J Cardiol. 76:1995;381-385.
18. Grassi G, Giannattasio C, Failla M, et al. Sympathetic modulation of radial artery compliance in congestive heart failure. Hypertension. 25:1995;348-354.
19. Grossman E, Messerli F, Oren S, et al. Disparate cardiovascular response to stress tests during isradipine and fosinopril therapy. Am J Cardiol. 72:1993;574-579.
20. Giannattasio C, Failla M, Stella ML, et al. Angiotensin-converting enzyme inhibition and radial artery compliance in patients with congestive heart failure. Hypertension. 26:1995;491-496.
21. Deedwania P. Clinical profile of fosinopril, a novel phosphinic acid ACE-inhibitor for the treatment of heart failure. Heart Failure. 11(3):1995;125-126.
22. Brown EJ, Chew PH, MacLean A, et al. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol. 75:1995;596-600.
23. Erhardt L, Maclean A, Ilgenfritz J, et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J. 16:1995;1892-1899.
24. Duchin KL. Clinical pharmacology of fosinopril. Drug Invest. 3(suppl 4):1991;12-17.
25. Duchin KL, Kripalani KJ, Marino MR, et al. Review of the pharmacokinetics of fosinopril in special population. Drug Invest. 3(suppl 4):1991;18-24.
26. David D, Jallad N, Germino FW, et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor associated cough. Am J Ther. 2:1995;806-813.
27. Germino FW, Lastra J, Pool P, et al: Evaluation of the cough profile of fosinopril in hypertensive patients with ACE inhibitor associated cough - A pilot study. Curr Ther Res 1993;54:469-457.
28. Galatius-Jensen S, Wroblewski H, Emmeluth C, et al. Plasma endothelin in congestive heart failure effect of the ACE inhibitor, fosinopril . Cardiovasc Res. 32:1996;1148-1154.